DMDanizat Z. Masaeva

Danizat Z. Masaeva

*This is an algorithmically generated author record based on publicly available information.

Danizat Z. Masaeva has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effect of internal carotid artery stenting on brain vascularization

    by D.G. Ioseliani, T.S. Sandodze, Yu.N. Yusef, M.KH. Durzhinskaya, E.E. Kazaryan, S.P. Semitko, N.V. Tsereteli, V.G. Pavlov, D.Z. Masaeva

    Cerebral microcirculation after internal carotid artery (ICA) stenting is an insufficiently explored and relevant area of research. To address this question, we studied blood circulation in the eye as a part of central nervous system supplied through ICA. Objective. To evaluate the effect of ICA stenting on eye vascularization in early period. Materials and methods. The study included 92 patients with unilateral or bilateral ICA stenosis ≥70% who underwent stenting of one ICA. Prior to the intervention and 3—7 days later, patients underwent optical coherence tomography (OCT). We measured microvascular network density using VAD (image binarization method) and VSD (skeletonizing method) modes in superficial (SCP) and deep (DCP) layers of macular retina in the area 6×6 mm (VAD SCP MZ 6×6 mm, VAD DCP MZ 6x6 mm, VSD SCP MZ 6x6 mm, VSD DCP MZ 6x6 mm) and in peripapillary (RPC) region in the area 4x4 mm (VAD RPC 4×4 mm, VSD RPC 4×4 mm). We distinguished 2 groups depending on eye lateralization: group 1 — ipsilateral eyes, group 2 — contralateral eyes. There were no differences in baseline OCTA parameters between ipsilateral and contralateral eyes. Results. ICA stenting was followed by significant increase of VAD DCP MZ 6×6 mm and VSD DCP MZ 6×6 mm in ipsilateral (p=0.01 and p<0.01, respectively) and contralateral eyes (p=0.03 and p=0.01, respectively). This indicated better microcirculation in deep retinal plexus. Conclusion. Monitoring of retinal vascularization may be convenient for assessing the efficacy of ICA stenting regarding brain perfusion.

  • Open Access

    The role of deferred stenting in the treatment of ST-elevation myocardial infarction: a systematic review and meta-analysis

    by Alexey V. Azarov, Maria G. Glezer, Andrey S. Zhuravlev, Avtandil M. Babunashvili, Sergey P. Semitko, Ionatan R. Rafaeli, Il'YA A. Kovalchuk, Inomali K. Kamolov, Danizat Z. Masaeva, David G. Ioseliani

    Background: There have been a big number of studies assessing the efficacy of delayed coronary artery stenting (DCAS) in the prevention of no-reflow microvasculature injury compared to the standard immediate coronary artery stenting (ICAS) in ST-segment elevation myocardial infarction (STEMI). However, the results of these studies are contradictory in a lot of ways. Aim: To summarize studies on the assessment of DCAS in the prevention of no-reflow compared to the standard ICAS. Materials and methods: We performed a systematic literature search in PubMed, Google Scholar, and eLIBRARY.RU databases. The analysis included 17 studies with a total sample of 3505 patients. The comparative analysis included angiography-based endpoints prevalence of no-reflow (thrombolysis in myocardial infarction, TIMI 3 and myocardial blush grade, MBG 2, corrected TIMI frame count, CTFC) and clinical endpoints of all-cause mortality, cardiovascular mortality, major adverse cardiac events (MACE), recurrent myocardial infarction and recurrent revascularization. In addition, the analysis included the assessment of ST-elevation resolution, left ventricular ejection fraction values in the delayed post-intervention period and between-group differences. Results: The no-reflow phenomenon was significantly less frequent in the DCAS groups for the following parameters: epicardial flow TIMI 3 (odds ratio (OR) 2.00; 95% confidence interval (CI) 1.492.69; p 0.00001; I = 16%), myocardial perfusion MBG 2 (OR 4.69; 95% CI 1.9811.14; p = 0.0005; I = 59%), CTFC (mean difference (MD) 10.29; 95% CI 0.9619.62; p = 0.03; I = 96%). The analysis of secondary endpoints showed that MACE were less frequent in the DCAS groups (OR 1.29; 95% CI 1.041.60; p = 0.02; I = 42%), the difference becoming more significant in the studies with high initial thrombotic burden (TTG 3) (OR 1.83; 95% CI 1.282.62; p = 0.0009; I = 41%). The most clinically significant decrease of the MACE rate was found in 5 studies (n = 656) with high initial thrombotic burden (TTG 3) and mean time to repeated intervention from 4 to 7 days (OR 3.15; 95% CI 1.865.32; p 0.0001; I = 0%). The reverse trend for a benefit in the ICAS group was observed in the studies with a high initial thrombotic burden (TTG 3) and mean time to recurrent intervention of 48 hours (OR 0.60; 95% CI 0.301.19; p = 0.14; I = 20%). The ICAS and DCAS groups did not differ in overall mortality (p = 0.31), cardiovascular mortality (p = 0.49), repeated revascularization (p = 0.66), and ST resolution of 70% (p = 0.65). In the DCAS groups, there was an obvious trend to lower incidence of recurrent myocardial infarction (OR 1.28; 95% CI 0.951.73; p = 0.10; I = 0%), as well as to higher myocardial mass during the deferred analysis of left ventricular ejection fraction (OR -0.79; 95% CI -1.61 -0.04; p = 0.06; I = 36%). Conclusion: Deferred coronary artery stenting is an effective method for prevention of no-reflow. In patients with extended coronary thrombosis (TTG 3) and STEMI, the DCAS technique with time to recurrent intervention of 4 to 7 days decreases the probability of MACE compared to that with immediate stenting of the index coronary artery.